Inhibition of collagen cross-links by novel LOXL2 selective inhibitors in an in-vitro model of fibroblastic foci of IPF Source: International Congress 2016 – Common mechanisms in lung development and fibrosis Year: 2016
Collagen V activation and matrix extracellular remodeling mediated pulmonary fibrosis in experimental models of bleomycin and 3-5-di-tert-4-hidroxitoluene Source: Annual Congress 2013 –Growth factors at the crossroads of acute and chronic inflammation Year: 2013
Mast cells and fibroblasts work in concert to aggravate pulmonary fibrosis: Role of transmembrane SCF and PAR-2/PKCalpha/Raf-1/p44/42 signaling pathway Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis and rarities Year: 2013
Development of secretory leukocyte protease inhibitor (SLPI) variants resistant to degradation by neutrophil elastase Source: International Congress 2014 – New studies into pulmonary proteases and antiproteases Year: 2014
SH2 domain-containing phosphatase-SHP-2 is a novel anti-fibrotic regulator in pulmonary fibrosis Source: International Congress 2016 – Emerging concepts in lung disease pathogenesis Year: 2016
Targetingpyruvate kinase M2 isoform inhibits proliferation of human lung fibroblasts Source: International Congress 2016 – ILD: from the bench to the bedside Year: 2016
ATF3 regulates PINK1 transcription in lung epithelial cells of the aging lung Source: International Congress 2016 – Repair pathways: from lung development to ageing of the lung Year: 2016
Investigating the role of cathepsin S in the pathogenesis of cystic fibrosis-like lung disease Source: International Congress 2015 – Therapeutic approaches in inflammatory lung disease Year: 2015
Proteasome function in lung fibrosis Source: Annual Congress 2013 –Growth factors at the crossroads of acute and chronic inflammation Year: 2013
Alveolar type II cells transplantation decrease fibrocyte migration in pulmonary fibrosis Source: Annual Congress 2013 –Novel mechanisms in lung injury Year: 2013
The effect of dasatinib, a novel tyrosine kinase inhibitor, on the regression of pulmonary fibrosis in mice Source: International Congress 2014 – New and old players in fibrotic lung disease Year: 2014
Strong reversal of the lung fibrosis disease signature by autotaxin inhibitor GLPG1690 in a mouse model for IPF Source: International Congress 2016 – Therapeutic horizons: novel targets and pharmacological models Year: 2016
PBI-compound, a novel first-in-class anti-inflammatory/fibrotic compound, reduces bleomycin-induced idiopathic pulmonary fibrosis by regulation of extracellular matrix remodelling Source: Annual Congress 2013 –Novel mechanisms in lung injury Year: 2013
Bromodomain inhibitor JQ1 attenuates TGF-beta-suppressed SOD2 expression and reduces proliferation in human primary pulmonary fibroblasts Source: Annual Congress 2013 –The multiple faces of stress in lung injury Year: 2013
Pre-clinical evaluation of a novel and selective PI3K δ/gamma inhibitor in pulmonary fibrosis Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014
BmTI-A, a serine protease inhibitor, reduces the chronic allergic lung inflammation in a mice model Source: International Congress 2015 – Novel treatments for cough, asthma, COPD and bronchiectasis Year: 2015
Inhibitor effect of Janus kinase II in bleomycin-induced pulmonary fibrosis model Source: International Congress 2014 – New drugs for asthma, COPD and pulmonary fibrosis Year: 2014
Regulation of autophagy in amiodarone induced pulmonary fibrosis Source: Annual Congress 2013 –The vulnerable patient and ageing cells Year: 2013
Matrix metalloproteinase-2 is protective in bleomycin-induced pulmonary fibrosis Source: International Congress 2015 – Animal studies of asthma and other inflammatory conditions Year: 2015
SerpinB1 in cystic fibrosis airway fluids: quantity, molecular form and mechanism of elastase inhibition Source: Eur Respir J 2011; 37: 1083-1090 Year: 2011